Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00851929 · ClinicalTrials.gov registry record · Phase 2
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
A Phase 2 study of Pulmonary Hypertension and Sarcoidosis, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT00851929: Completed Phase 2 study of Pulmonary Hypertension and Sarcoidosis, sponsored by Medical University of South Carolina.
NCT00851929 is a Phase 2 study of Pulmonary Hypertension and Sarcoidosis that has completed, run by Medical University of South Carolina. The registered enrollment target is 16 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00851929, a Phase 2 study of Pulmonary Hypertension and Sarcoidosis, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis
Conditions Studied
Interventions
- DRUG Ambrisentan
Study Locations (2)
North Carolina
- University of North Carolina Medical Center - Chapel Hill
South Carolina
- Medical Univerrsity of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
What the finished NCT00851929 record still lists
NCT00851929 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Ambrisentan is the first listed.
NCT00851929 reports a single indexed study location in North Carolina, South Carolina.
Frequently Asked Questions
What is clinical trial NCT00851929 about?
NCT00851929 is a clinical study titled "Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension". Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis
What is the current status of trial NCT00851929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2008-11. Estimated completion is 2011-11.
What conditions does trial NCT00851929 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Sarcoidosis.
What interventions are being tested in trial NCT00851929?
The interventions under investigation include: Ambrisentan (DRUG).
Who is sponsoring clinical trial NCT00851929?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00851929 being conducted?
This trial has 2 study locations across North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00851929's enrollment target sits among peer trials
16 64th of 72 higher than 9 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia